Glycated Albumin Assay Market, by Product Type (Human Glycated Albumin Assay and Animal Glycated Albumin Assay), by Application (Diagnostics (Prediabetes, Type 1 Diabetes, and Type 2 Diabetes) and Research), by End User (Hospital, Diagnostic Centers, Research Centers, and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Feb 2023

Code : CMI1915

Pages :208

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Leading Companies

Global Glycated Albumin Assay Market: Key Players

Major players operating in the global glycated albumin assay market include Asahi Kasei Pharma Corporation, Weldon Biotech, Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbot, Diazyme Laboratories, Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co.,Ltd., LifeSpan BioSciences Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., DxGen Corp.

On February 2, 2023, Biocompare, a life science product directory, announced its acquisition with Scilan, a leading provider of artificial intelligence and machine learning based solutions for life science tool providers which will help Biocompare in developing new artificial intelligence based glycated albumin assays.

On 24 January 2023, Diazyme Laboratories, Inc., a certified medical device manufacturer, announced that it has entered into a partnership with Carolina Liquid Chemistries Corp, a leading provider of chemistry instruments and reagents.

In June 2019, Abbott India Ltd., which is one of the leading multinational pharmaceutical companies, launches first-ever rapid point-of-care hba1c test to aid in the diagnosis of diabetes.

On January 17 July, , EKF Diagnostics Holdings plc, which is a global medical diagnostics business, launched Lucica Glycated Albumin-LA specific test for glycated albumin.